Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Jan 23, 2018 → Jun 25, 2020

About Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category is a phase 3 stage product being developed by Aquestive Therapeutics for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT03428360. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (6) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03428360Phase 3Completed

Competing Products

20 competing products in Epilepsy

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35